APR 03, 2018 12:59 PM PDT

New Compound Stimulates Cancer-Killing Invariant Natural Killer T Cells

WRITTEN BY: Kara Marker

Stimulating the immune system to better fight cancer and infections is now possible with a synthesized compound called AH10-7. Researchers from the University Connecticut show in their new study how this compound can stimulate powerful immune cells that kill tumors and attack pathogens: invariant natural killer T cells.

AH10-7 (yellow), an antigen-presenting cell (gray), and an invariant natural killer T cell (green and blue) that spark activation of iNKT cells. Credit: Jose Gascon/UConn

Invariant natural killer T (iNKT) cells are known to defend the body against all types of dangers: infection, cancer, and autoimmune diseases like multiple sclerosis and lupus. They are cells of the immune system that experts describe as living in a “poised effector state.” This means that after they are activated, iNKT cells quickly and continuously produce cytokines, chemical messengers of the immune system that either suppress or activate the inflammatory response.

Over the past several years, researchers have been studying ways to better stimulate iNKT cells to protect the body. Research has focused on both natural and synthetic forms of glycolipid ligands known as alpha-galactosylceramides (alpha-GalCers). Alpha-GalCers are particularly gifted at activating iNKT cells because they facilitate the interactions between antigen-presenting cells, like macrophages or dendritic cells, and iNKT cells so they can be activated to fight cancer or infections.

A compound called KRN7000 was the first ever synthesized alpha-GalCer to successfully stimulate iNKT cells. However, KRN7000 initiated the production of various cytokines, and researchers wanted a compound that selectively initiated the release of just one cytokine: Th1, which has anti-cancer activity.

In the new study, scientists introduce a compound called AH10-7. Unlike KRN7000, AH10-7 selectively activates Th1 cytokines, maximizing the benefit of using it to activate iNKT cells. AH10-7 was created with two major chemical modifications to make it so.

"We are providing protocols so that other scientists can rationally design related molecules that elicit desired responses from iNKT cells,” said chemist Jose Gascon.

Study leader Amy Howell has been investigating glycolipids and the human immune system for more than two decades. "One of the goals in this field has been to identify compounds that elicit a more biased or selective response from iNKT cells, and we were able to incorporate features in AH10-7 that did that," she said.

Howell and her team successfully tested AH10-7 in mice genetically altered to imitate the human iNKT response; the synthesized compound was at least as effective as KRN7000 at blocking the growth of melanoma.

Researchers also incorporated advanced structural and 3D computer modeling analysis to evaluate the components of AH10-7 that maximize its success with stimulating iNKT cells. By examining the molecular interaction between iNKT cell receptors and AH10-7, researchers saw several structural factors as providing a foundation for AH10-7’s unique ability to activate iNKT cells.

The present study was published in the journal Cell Chemical Biology.

Sources: Clinical Immunology, Nature Reviews Immunology, University of Connecticut

About the Author
  • I am a scientific journalist and enthusiast, especially in the realm of biomedicine. I am passionate about conveying the truth in scientific phenomena and subsequently improving health and public awareness. Sometimes scientific research needs a translator to effectively communicate the scientific jargon present in significant findings. I plan to be that translating communicator, and I hope to decrease the spread of misrepresented scientific phenomena! Check out my science blog: ScienceKara.com.
You May Also Like
SEP 09, 2021
Cancer
Can a Mole Fight Melanoma?
SEP 09, 2021
Can a Mole Fight Melanoma?
About 30% of melanoma cases arise from an existing nevus.  More commonly known as moles, Nevi are skin growths that ...
SEP 03, 2021
Cell & Molecular Biology
Is a Venom-Like Molecule Involved in COVID-19 Mortality?
SEP 03, 2021
Is a Venom-Like Molecule Involved in COVID-19 Mortality?
Scientists have sought to learn more about why some people get severe COVID-19 while others have only mild cases. We kno ...
SEP 09, 2021
Drug Discovery & Development
Can vaccines help prevent and treat opioid addiction?
SEP 09, 2021
Can vaccines help prevent and treat opioid addiction?
According to the United States Centers for Disease Control (CDC), 136 people die from an opioid overdose every ...
SEP 12, 2021
Coronavirus
Real-World, Post-Delta COVID-19 Vaccine Data & Potential Treatment
SEP 12, 2021
Real-World, Post-Delta COVID-19 Vaccine Data & Potential Treatment
New research may have identified a potential treatment or preventive medication for SARS-CoV-2 and other viral infection ...
SEP 27, 2021
Cell & Molecular Biology
Newly Identified Cell Type is Linked to Chronic Skin Disorders
SEP 27, 2021
Newly Identified Cell Type is Linked to Chronic Skin Disorders
The chronic skin disease atopic dermatitis (AD) is estimated to affect about 15 percent of children worldwide, and for s ...
OCT 12, 2021
Drug Discovery & Development
Preventing future pandemics - Scientists developing broadly protective vaccines against coronaviruses
OCT 12, 2021
Preventing future pandemics - Scientists developing broadly protective vaccines against coronaviruses
Researchers at Japan’s Osaka University recently developed and tested a novel vaccine that may protect a ...
Loading Comments...